Prime Medicine, Inc.
PRME evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $604.9M
- Lead Asset:
- pm359 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for PRME—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PRME
Prime Medicine, Inc. (PRME) is a biotechnology company developing prime editing-based, one-time curative genetic therapies for diseases caused by defined genetic alterations, with lead programs in Wilson disease, alpha-1 antitrypsin deficiency (AATD), and chronic granulomatous disease (CGD).
Key risk: No product revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$604.9M
Cash Runway
—
Lead Asset
pm359 (Phase 1/Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for Prime Medicine, Inc..
Prime Medicine, Inc. (PRME) is a biotechnology company developing prime editing-based, one-time curative genetic therapies for diseases caused by defined genetic alterations, with lead programs in Wilson disease, alpha-1 antitrypsin deficiency (AATD), and chronic granulomatous disease (CGD).
- Cash & equivalents of $47.5M as of 2026-06-30 [sec].
- Net income of -$42.1M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $39.8M as of 2026-06-30 [sec].
- Received CTA clearance in New Zealand (June 2026) and IND clearance from the FDA (July 2026) for PM577a, a Prime Editor for Wilson disease [sec_mda].
- On track to file IND/CTA for Wilson disease (1H 2026) and AATD (mid-2026) programs, with initial clinical data expected in 2027 [news].
What works
- First clinical authorization for an in vivo Prime Editing therapy achieved: CTA clearance for PM577a in New Zealand and IND clearance from the FDA [sec_mda].
- Cash runway into 2027, with $191M in cash, cash equivalents, investments, and restricted cash reported as of March 2026 [news].
- Multiple pipeline programs advancing, including ex vivo PM359 for CGD (Phase 1/2) and preclinical programs for cystic fibrosis and CAR-T (with BMS) [sec_mda].
What to weigh
- No revenue from product sales; company expects expenses to increase substantially as it advances preclinical and clinical activities [sec_mda].
- Net loss of $42.1M for the period ending 2026-06-30 [sec].
- Uncertainty about when or if any product candidate will be successfully developed, approved, or commercialized [sec_mda].
From the filings
Quoted directly from source documents.
First clinical authorization for an in vivo Prime Editing therapy
“In June 2026, we received clearance of the CTA for PM577a, an investigational Prime Editor for Wilson disease, in New Zealand, representing the first clinical authorization for one of our in vivo Prime Editing therapies”
SEC MD&A · August 6, 2026
Cash runway into 2027
“Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027”
News · March 3, 2026
No revenue from product sales expected until successful development and approval
“do not expect to generate revenue from product sales unless and until we successfully complete preclinical and clinical development of, receive regulatory approval for, and commercialize a product candidate”
SEC MD&A · May 7, 2026
IND clearance for PM577a in the US
“In July 2026, the FDA cleared our IND application for PM577a. The IND clearance opens participation in our global Phase 1/2 clinical trial to patients in the United States”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2024-10-17 · Phase 1/2 start for PM359 (CGD) — A Phase 1/2 study evaluating ex vivo Prime Editing in participants with autosomal recessive CGD due to NCF1 mutations.
- 2026-09-01 · Phase 1/2 start for PM577a (Wilson disease) — A Phase 1/2 clinical study to evaluate safety, tolerability, biological activity, and initial efficacy of PM577a.
Risks & what to watch (3)›
Key risks
- No product revenue — Company does not expect revenue from product sales until successful development, approval, and commercialization [sec_mda].
- Substantial expense increase — Expenses expected to increase substantially as preclinical and clinical activities advance [sec_mda].
- Development uncertainty — Uncertainty about when or if any product candidate will be successfully developed or approved [sec_mda].
What to watch
- IND/CTA filings for Wilson disease (1H 2026) and AATD (mid-2026) programs [news].
- Initial clinical data for Wilson disease and AATD expected in 2027 [news].
- BLA submission for PM359 in CGD following final alignment with FDA [news].
- Cash burn rate and whether cash runway extends beyond 2027 [news].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Prime Medicine, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Prime Medicine, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 5.26 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 21.5%
- Days to cover
- 16.4
- Shares short
- 30,352,640
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRME short interestGovernance
Frequently asked questions
What is the AI investment thesis for Prime Medicine, Inc.?
Prime Medicine, Inc. (PRME) is a biotechnology company developing prime editing-based, one-time curative genetic therapies for diseases caused by defined genetic alterations, with lead programs in Wilson disease, alpha-1 antitrypsin deficiency (AATD), and chronic granulomatous disease (CGD).
What is Prime Medicine, Inc.'s lead drug candidate?
Prime Medicine, Inc.'s most advanced tracked candidate is pm359 (Phase 1/Phase 2) for Chronic Granulomatous Disease.
Who is the CEO of Prime Medicine, Inc.?
Dr. Allan Reine M.D. is the chief executive officer of Prime Medicine, Inc. (PRME).
Where is Prime Medicine, Inc. headquartered?
Prime Medicine, Inc. (PRME) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Prime Medicine, Inc. focus on?
Prime Medicine, Inc. develops therapies across Oncology, Rare Disease, Gene Therapy, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.